{
  "docId": "019de070-19a4-704e-b5bc-b8f4ae0c7550",
  "docSlug": "2cfade3d34acc49c8d5f05063b654956",
  "documentTitle": "ATAI | Investor Presentation Deck | 49 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2020-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 31,
  "pageCount": 49,
  "prevPage": 30,
  "nextPage": 32,
  "slideType": "comparison_table",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 14,
  "notes": "The table uses checkmarks to indicate positive attributes for various therapies, highlighting DMX-1002's unique profile.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-19a4-704e-b5bc-b8f4ae0c7550/31",
  "deckHref": "/decks/019de070-19a4-704e-b5bc-b8f4ae0c7550",
  "deckJsonHref": "/decks/019de070-19a4-704e-b5bc-b8f4ae0c7550.json",
  "deckAnchorHref": "/decks/019de070-19a4-704e-b5bc-b8f4ae0c7550#slide-31",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.2,
        "x": 0.05,
        "y": 0.22
      },
      "kind": "paragraph",
      "text": "DMX-1002 could potentially become a paradigm-shifting therapy for Opioid Use Disorder",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dd81e9f6-a7fc-46e5-9b0f-5e800a442387",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.26,
        "y": 0.91
      },
      "kind": "source-note",
      "text": "Source: GlobalData, Evaluate Pharma (both as of 2021). (1) Current Standard of Care. (2) Rarely used given high rates of relapse. Used primarily in institutional or penitentiary settings",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7e217371-b440-413a-9db1-4a4d7eefedcc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.7,
        "x": 0.26,
        "y": 0.21
      },
      "kind": "table",
      "text": "Comparison matrix of DMX-1002 vs Clonidine, Lofexidine, Methadone, Buprenorphine, Naltrexone across 5 clinical criteria.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "af677355-06d9-49aa-a25b-f17c1afd7766",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.7,
        "x": 0.26,
        "y": 0.08
      },
      "kind": "title",
      "text": "DMX-1002 has the potential to become the first & best in-class treatment for OUD, minimizing risk of relapse",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dfb7d2c1-2bdd-4d05-a9c4-3e5ad61a9a63",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "4823e4eb-a22d-49be-b4df-9e3ad0bd408a",
      "evidence": "table/data: Comparison matrix of DMX-1002 vs Clonidine, Lofexidine, Methadone, Buprenorphine, Naltrexone across 5 clinical criteria.",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "comparison_table",
      "slug": null,
      "matchId": "0b4f1e50-6d64-451a-8e7e-acd7de77fc8b",
      "evidence": "Structured grid comparing product features against competitors",
      "confidence": 1
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}